Fire accelerates assimilation and transfer of photosynthetic carbon from plants to soil microbes in a northern peatland

Northern peatlands are recognized as globally important stores of terrestrial carbon (C), yet we have limited understanding of how global changes, including land use, affect C cycling processes in these ecosystems. Making use of a long-term (>50 year old) peatland land management experiment in the UK, we investigated, using a 13CO2 pulse chase approach, how managed burning and grazing influenced the short-term uptake and cycling of C through the plant–soil system. We found that burning affected the composition and growth stage of the plant community, by substantially reducing the abundance of mature ericoid dwarf-shrubs. Burning also affected the structure of the soil microbial community, measured using phospholipid fatty acid analysis, by reducing fungal biomass. There was no difference in net ecosystem exchange of CO2, but burning was associated with an increase in photosynthetic uptake of 13CO2 and increased transfer of 13C to the soil microbial community relative to unburned areas. In contrast, grazing had no detectable effects on any measured C cycling process. Our study provides new insight into how changes in vegetation and soil microbial communities arising from managed burning affect peatland C cycling processes, by enhancing the uptake of photosynthetic C and the transfer of C belowground, whilst maintaining net ecosystem exchange of CO2 at pre-burn levels

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events